Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $19.19 and last traded at $18.30, with a volume of 61735 shares trading hands. The stock had previously closed at $16.94.
Wall Street Analyst Weigh In
A number of research analysts have commented on the company. HC Wainwright assumed coverage on Maze Therapeutics in a report on Wednesday. They set a "buy" rating and a $34.00 target price on the stock. Wedbush assumed coverage on Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price on the stock. Finally, Guggenheim reaffirmed a "buy" rating and set a $19.00 target price on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Maze Therapeutics currently has a consensus rating of "Buy" and an average price target of $25.60.
Read Our Latest Report on MAZE
Maze Therapeutics Price Performance
The company has a 50-day moving average of $13.07.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).
Institutional Trading of Maze Therapeutics
Several large investors have recently added to or reduced their stakes in the business. TRV GP IV LLC acquired a new stake in Maze Therapeutics in the 1st quarter valued at approximately $66,874,000. Frazier Life Sciences Management L.P. acquired a new stake in Maze Therapeutics in the 1st quarter valued at approximately $45,460,000. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics in the 1st quarter valued at approximately $45,362,000. Matrix Capital Management Company LP acquired a new stake in Maze Therapeutics in the 1st quarter valued at approximately $27,373,000. Finally, Alphabet Inc. acquired a new stake in Maze Therapeutics in the 1st quarter valued at approximately $26,561,000.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access